Maravai LifeSciences (MRVI) News
Filter MRVI News Items
MRVI News Results
|Loading, please wait...|
MRVI News Highlights
- MRVI's 30 day story count now stands at 7.
- Over the past 21 days, the trend for MRVI's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about MRVI are DRUG, INMD and LAB.
Latest MRVI News From Around the Web
Below are the latest news stories about MARAVAI LIFESCIENCES HOLDINGS INC that investors may wish to consider to help them evaluate MRVI as an investment opportunity.
5.6% earnings growth over 1 year has not materialized into gains for Maravai LifeSciences Holdings (NASDAQ:MRVI) shareholders over that period
Taking the occasional loss comes part and parcel with investing on the stock market. Anyone who held Maravai...
2 Top Biotech Stocks to Buy In March and Hold Forever
Most biotech companies are too risky to even think about holding forever. Between the big risk of a clinical trial blowing up and the lesser risk of getting one-upped by a competitor's medicine even after successfully moving a drug from the lab to the market, it's incredibly difficult to feel confident in a biotech's long-term future. Moderna (NASDAQ: MRNA) is a biotech stock that needs no introduction after successfully commercializing its coronavirus vaccine and raking in $18.8 billion in revenue in 2022 as a result.
Will Maravai LifeSciences Holdings (MRVI) be a Long-Term Compounder in Your Portfolio?
ClearBridge Investments, an investment management company, published its “ClearBridge Small Cap Value Strategy” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the strategy outperformed the Russell 2000 Value Index. On an absolute basis, the strategy gained in nine out of eleven sectors it was invested in […]
Maravai LifeSciences Announces March 2023 Investor Conference Schedule
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of March. On March 15, 2023, at 2:00 p.m. PST, Kevin Herde, Chief Financial Officer, and Deborah Barbara, Vice President, Strategy and Business Development will participate in a fireside chat at the Barclays Global Healthcare Confere
13 Most Undervalued Healthcare Stocks To Buy According To Hedge Funds
In this article, we will take a look at the 13 most undervalued healthcare stocks to buy according to hedge funds. To see more such companies, go directly to 5 Most Undervalued Healthcare Stocks To Buy According To Hedge Funds. According to a report by T.Rowe Price, healthcare stocks can be generally divided into two […]
Don't Miss Out on These 2 Undervalued Stocks With Huge Growth Potential
The market doesn't always get a growth stock's valuation right, and when it's wrong, there's often an opportunity to make a hearty dollop of dosh -- and it's always good to feel as if you're a step ahead of the market. On that note, two growth stocks look favorably priced right now, and there's good reason to think they'll keep growing in the years ahead. Israeli medical aesthetics company InMode (NASDAQ: INMD) is a stellar investment opportunity thanks to its slightly cheap shares and its finely tuned growth engine.
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Could Be 28% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Maravai LifeSciences Holdings fair value estimate is US$19.82...
Maravai LifeSciences (MRVI) Q4 2022 Earnings Call Transcript
Trey Martin, president of biologic safety testing; and Becky Buzzeo, our chief commercial officer, will join the call for the question-and-answer session following the prepared remarks. As Slide 6 indicates, 2022 was an incredible year for the entire business.
Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q4 Earnings Estimates
Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 2.94% and 0.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Maravai LifeSciences Reports Fourth Quarter and Full Year 2022 Financial Results
Base business revenues, excluding COVID-19 related CleanCap® revenues, were up 67% in the fourth quarter and up 17% for the full year Announces acquisition of privately-held Alphazyme, LLC, adding critical enzyme manufacturing capabilities to Maravai’s Nucleic Acid Production Segment SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reporte